Fibrosing interstitial lung disease - Yttrium therapy Factor
Last reviewed for CCPS 16 December 2009.
Preliminary questions [40667]
40686 there is some evidence that yttrium-90 microspheres as therapy may be a factor in the development or worsening of the condition under consideration.
40994 the veteran has received yttrium-90 microspheres as therapy at some time.
40995 the veteran received yttrium-90 microspheres as therapy for primary and metastatic liver tumours.
40996 — the veteran received yttrium-90 microspheres as therapy for treatment of an illness or injury which is identifiable.
40999 — the veteran has established the causal connection between yttrium-90 microspheres as therapy and VEA service for fibrosing interstitial lung disease.
for treatment of the identified illness or injury, the veteran received yttrium-90 microspheres as therapy before the clinical onset of fibrosing interstitial lung disease.41000 — the veteran has established the causal connection between yttrium-90 microspheres as therapy and VEA service for the clinical onset of fibrosing interstitial lung disease.
41002 — the veteran has established the causal connection between yttrium-90 microspheres as therapy and operational service for the clinical onset of fibrosing interstitial lung disease.
or
41003 — the veteran has established the causal connection between yttrium-90 microspheres as therapy and eligible service for the clinical onset of fibrosing interstitial lung disease.
or
the clinical onset of the condition under consideration occurred after the end of the veteran's last period of VEA service. the condition under consideration permanently worsened. for treatment of the identified illness or injury, the veteran received yttrium-90 microspheres as therapy before the clinical worsening of fibrosing interstitial lung disease.41001 — the veteran has established the causal connection between yttrium-90 microspheres as therapy and VEA service for the clinical worsening of fibrosing interstitial lung disease.
41004 — the veteran has established the causal connection between yttrium-90 microspheres as therapy and operational service for the clinical worsening of fibrosing interstitial lung disease.
or
41005 — the veteran has established the causal connection between yttrium-90 microspheres as therapy and eligible service for the clinical worsening of fibrosing interstitial lung disease.
Clinical onset and operational service [41002]
41006 — the identified illness or injury, for which the veteran received yttrium-90 microspheres as therapy, is causally related to operational service.
Clinical onset and eligible service [41003]
41007 — the identified illness or injury, for which the veteran received yttrium-90 microspheres as therapy, is causally related to eligible service.
Clinical worsening and operational service [41004]
41006 — the identified illness or injury, for which the veteran received yttrium-90 microspheres as therapy, is causally related to operational service.
the clinical onset of the condition under consideration occurred prior to that part of operational service to which the identified illness or injury, for which the veteran received yttrium-90 microspheres as therapy, is causally related.Clinical worsening and eligible service [41005]
41007 — the identified illness or injury, for which the veteran received yttrium-90 microspheres as therapy, is causally related to eligible service.
the clinical onset of the condition under consideration occurred prior to that part of eligible service to which the identified illness or injury, for which the veteran received yttrium-90 microspheres as therapy, is causally related.